ANI Pharmaceuticals Statistics
Share Statistics
ANI Pharmaceuticals has 21.02M shares outstanding. The number of shares has increased by -0.24% in one year.
| Shares Outstanding | 21.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.06% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 17.42M |
| Failed to Deliver (FTD) Shares | 29.78K |
| FTD / Avg. Volume | 11.5% |
Short Selling Information
The latest short interest is 2.35M, so 11.18% of the outstanding shares have been sold short.
| Short Interest | 2.35M |
| Short % of Shares Out | 11.18% |
| Short % of Float | 13.5% |
| Short Ratio (days to cover) | 8.69 |
Valuation Ratios
The PE ratio is 52.86 and the forward PE ratio is 11.03. ANI Pharmaceuticals 's PEG ratio is 0.07.
| PE Ratio | 52.86 |
| Forward PE | 11.03 |
| PS Ratio | 2.04 |
| Forward PS | 1.5 |
| PB Ratio | 2.17 |
| P/FCF Ratio | 9.88 |
| PEG Ratio | 0.07 |
Enterprise Valuation
ANI Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.09B.
| EV / Earnings | 57.87 |
| EV / Sales | 2.23 |
| EV / EBITDA | 10.2 |
| EV / EBIT | 23.14 |
| EV / FCF | 10.82 |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.62.
| Current Ratio | 3.57 |
| Quick Ratio | 2.81 |
| Debt / Equity | 0.62 |
| Total Debt / Capitalization | 38.43 |
| Cash Flow / Debt | 0.42 |
| Interest Coverage | 1.74 |
Financial Efficiency
Return on equity (ROE) is 0.04% and return on capital (ROIC) is 5.97%.
| Return on Equity (ROE) | 0.04% |
| Return on Assets (ROA) | 0.02% |
| Return on Capital (ROIC) | 5.97% |
| Revenue Per Employee | 758.28K |
| Profits Per Employee | 29.25K |
| Employee Count | 642 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.63 |
Taxes
| Income Tax | 1.09M |
| Effective Tax Rate | 0.06 |
Stock Price Statistics
The stock price has increased by -2.15% in the last 52 weeks. The beta is 0.71, so ANI Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | -2.15% |
| 50-Day Moving Average | 56.59 |
| 200-Day Moving Average | 60.88 |
| Relative Strength Index (RSI) | 43.51 |
| Average Volume (20 Days) | 258.97K |
Income Statement
In the last 12 months, ANI Pharmaceuticals had revenue of 486.82M and earned 18.78M in profits. Earnings per share was 0.95.
| Revenue | 486.82M |
| Gross Profit | 305.30M |
| Operating Income | 46.97M |
| Net Income | 18.78M |
| EBITDA | 106.60M |
| EBIT | 46.97M |
| Earnings Per Share (EPS) | 0.95 |
Balance Sheet
The company has 221.12M in cash and 285.67M in debt, giving a net cash position of -64.55M.
| Cash & Cash Equivalents | 221.12M |
| Total Debt | 285.67M |
| Net Cash | -64.55M |
| Retained Earnings | -80.13M |
| Total Assets | 1.29B |
| Working Capital | 331.36M |
Cash Flow
In the last 12 months, operating cash flow was 118.96M and capital expenditures -18.51M, giving a free cash flow of 100.45M.
| Operating Cash Flow | 118.96M |
| Capital Expenditures | -18.51M |
| Free Cash Flow | 100.45M |
| FCF Per Share | 5.58 |
Margins
Gross margin is 62.71%, with operating and profit margins of 9.65% and 3.86%.
| Gross Margin | 62.71% |
| Operating Margin | 9.65% |
| Pretax Margin | 4.08% |
| Profit Margin | 3.86% |
| EBITDA Margin | 21.9% |
| EBIT Margin | 9.65% |
| FCF Margin | 20.63% |
Dividends & Yields
ANIP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.75% |
| FCF Yield | 8.81% |
Analyst Forecast
The average price target for ANIP is $78.5, which is 44.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $78.5 |
| Price Target Difference | 44.8% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Jul 18, 2013. It was a backward split with a ratio of 1:6.
| Last Split Date | Jul 18, 2013 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 1.47 |
| Piotroski F-Score | 3 |